Lakefront Biotherapeutics (LKFT) Stock Statistics & Valuation Metrics

Lakefront Biotherapeutics has a market cap or net worth of $1.83B. The enterprise value is $1.47B.

Lakefront Biotherapeutics has 65,897,070 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lakefront Biotherapeutics’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 15.40%.

The current PE Ratio of Lakefront Biotherapeutics is 28.1. Lakefront Biotherapeutics’s PEG ratio is 0.00.

In the last 12 months, Lakefront Biotherapeutics had revenue of 1.11B and earned 320.88M in profits. Earnings per share was 4.87.

In the last 12 months, operating cash flow was -301.60M and capital expenditures -8.73M, giving a free cash flow of -310.33M billion.

Lakefront Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Lakefront Biotherapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Lakefront Biotherapeutics as a current ratio of 20.15, with Debt / Equity ratio of 0.20%

In the past 12 months, Lakefront Biotherapeutics has paid -18.62M in taxes.

Lakefront Biotherapeutics EV to EBITDA ratio is 4.24, with an EV/FCF ratio of -5.61.

Lakefront Biotherapeutics has $2.98B in cash and marketable securities with $6.43M in debt, giving a net cash position of $2.98B billion.

Gross margin is 98.01%, with operating margin of 45.08%, and net profit margin of 28.85%.

The average price target for Lakefront Biotherapeutics is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell